Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and β-YAC transgenic mice

Aluya R. Oseghale, Xingguo Zhu, Biaoru Li, Kenneth R. Peterson, Abraham Nudelman, Ada Rephaeli, Hongyan Xu, Betty Sue Pace

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pharmacologic induction of fetal hemoglobin (HbF) is an effective strategy for treating sickle cell disease (SCD) by ameliorating disease severity. Hydroxyurea is the only FDA-approved agent that induces HbF, but significant non-responders and requirement for frequent monitoring of blood counts for drug toxicity limit clinical usefulness. Therefore, we investigated a novel prodrug conjugate of butyric acid (BA) and δ-aminolevulinate (ALA) as a potential HbF inducing agent, using erythroid precursors and a preclinical β-YAC mouse model. We observed significantly increased γ-globin gene transcription and HbF expression mediated by AN-233 in K562 cells. Moreover, AN-233 stimulated mild heme biosynthesis and inhibited expression of heme-regulated eIF2α kinase involved in silencing γ-globin expression. Studies using primary erythroid precursors generated from sickle peripheral blood mononuclear cells verified the ability of AN-233 to induce HbF, increase histone H3 and H4 acetylation levels at the γ-globin promoter and reduce erythroid precursor sickling by 50%. Subsequent drug treatment of β-YAC transgenic mice confirmed HbF induction in vivo by AN-233 through an increase in the percentage of HbF positive red blood cells and HbF levels measured by flow cytometry. These data support the potential development of AN-233 for the treatment of SCD.

Original languageEnglish (US)
Article number102345
JournalBlood Cells, Molecules, and Diseases
Volume79
DOIs
StatePublished - Nov 1 2019

Fingerprint

Fetal Hemoglobin
Globins
Prodrugs
Transgenic Mice
Sickle Cell Anemia
Heme
Histones
Butyric Acid
Hydroxyurea
K562 Cells
Acetylation
Drug-Related Side Effects and Adverse Reactions
Blood Cells
Flow Cytometry
Phosphotransferases
Erythrocytes
Pharmaceutical Preparations
Genes

Keywords

  • AN-233
  • Butyric acid
  • Fetal hemoglobin
  • β-YAC mice
  • δ-Aminolevulinate

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and β-YAC transgenic mice. / Oseghale, Aluya R.; Zhu, Xingguo; Li, Biaoru; Peterson, Kenneth R.; Nudelman, Abraham; Rephaeli, Ada; Xu, Hongyan; Pace, Betty Sue.

In: Blood Cells, Molecules, and Diseases, Vol. 79, 102345, 01.11.2019.

Research output: Contribution to journalArticle

@article{537cfc64fdcc44c382499d959216d2ce,
title = "Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and β-YAC transgenic mice",
abstract = "Pharmacologic induction of fetal hemoglobin (HbF) is an effective strategy for treating sickle cell disease (SCD) by ameliorating disease severity. Hydroxyurea is the only FDA-approved agent that induces HbF, but significant non-responders and requirement for frequent monitoring of blood counts for drug toxicity limit clinical usefulness. Therefore, we investigated a novel prodrug conjugate of butyric acid (BA) and δ-aminolevulinate (ALA) as a potential HbF inducing agent, using erythroid precursors and a preclinical β-YAC mouse model. We observed significantly increased γ-globin gene transcription and HbF expression mediated by AN-233 in K562 cells. Moreover, AN-233 stimulated mild heme biosynthesis and inhibited expression of heme-regulated eIF2α kinase involved in silencing γ-globin expression. Studies using primary erythroid precursors generated from sickle peripheral blood mononuclear cells verified the ability of AN-233 to induce HbF, increase histone H3 and H4 acetylation levels at the γ-globin promoter and reduce erythroid precursor sickling by 50{\%}. Subsequent drug treatment of β-YAC transgenic mice confirmed HbF induction in vivo by AN-233 through an increase in the percentage of HbF positive red blood cells and HbF levels measured by flow cytometry. These data support the potential development of AN-233 for the treatment of SCD.",
keywords = "AN-233, Butyric acid, Fetal hemoglobin, β-YAC mice, δ-Aminolevulinate",
author = "Oseghale, {Aluya R.} and Xingguo Zhu and Biaoru Li and Peterson, {Kenneth R.} and Abraham Nudelman and Ada Rephaeli and Hongyan Xu and Pace, {Betty Sue}",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.bcmd.2019.102345",
language = "English (US)",
volume = "79",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and β-YAC transgenic mice

AU - Oseghale, Aluya R.

AU - Zhu, Xingguo

AU - Li, Biaoru

AU - Peterson, Kenneth R.

AU - Nudelman, Abraham

AU - Rephaeli, Ada

AU - Xu, Hongyan

AU - Pace, Betty Sue

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Pharmacologic induction of fetal hemoglobin (HbF) is an effective strategy for treating sickle cell disease (SCD) by ameliorating disease severity. Hydroxyurea is the only FDA-approved agent that induces HbF, but significant non-responders and requirement for frequent monitoring of blood counts for drug toxicity limit clinical usefulness. Therefore, we investigated a novel prodrug conjugate of butyric acid (BA) and δ-aminolevulinate (ALA) as a potential HbF inducing agent, using erythroid precursors and a preclinical β-YAC mouse model. We observed significantly increased γ-globin gene transcription and HbF expression mediated by AN-233 in K562 cells. Moreover, AN-233 stimulated mild heme biosynthesis and inhibited expression of heme-regulated eIF2α kinase involved in silencing γ-globin expression. Studies using primary erythroid precursors generated from sickle peripheral blood mononuclear cells verified the ability of AN-233 to induce HbF, increase histone H3 and H4 acetylation levels at the γ-globin promoter and reduce erythroid precursor sickling by 50%. Subsequent drug treatment of β-YAC transgenic mice confirmed HbF induction in vivo by AN-233 through an increase in the percentage of HbF positive red blood cells and HbF levels measured by flow cytometry. These data support the potential development of AN-233 for the treatment of SCD.

AB - Pharmacologic induction of fetal hemoglobin (HbF) is an effective strategy for treating sickle cell disease (SCD) by ameliorating disease severity. Hydroxyurea is the only FDA-approved agent that induces HbF, but significant non-responders and requirement for frequent monitoring of blood counts for drug toxicity limit clinical usefulness. Therefore, we investigated a novel prodrug conjugate of butyric acid (BA) and δ-aminolevulinate (ALA) as a potential HbF inducing agent, using erythroid precursors and a preclinical β-YAC mouse model. We observed significantly increased γ-globin gene transcription and HbF expression mediated by AN-233 in K562 cells. Moreover, AN-233 stimulated mild heme biosynthesis and inhibited expression of heme-regulated eIF2α kinase involved in silencing γ-globin expression. Studies using primary erythroid precursors generated from sickle peripheral blood mononuclear cells verified the ability of AN-233 to induce HbF, increase histone H3 and H4 acetylation levels at the γ-globin promoter and reduce erythroid precursor sickling by 50%. Subsequent drug treatment of β-YAC transgenic mice confirmed HbF induction in vivo by AN-233 through an increase in the percentage of HbF positive red blood cells and HbF levels measured by flow cytometry. These data support the potential development of AN-233 for the treatment of SCD.

KW - AN-233

KW - Butyric acid

KW - Fetal hemoglobin

KW - β-YAC mice

KW - δ-Aminolevulinate

UR - http://www.scopus.com/inward/record.url?scp=85069726890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069726890&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2019.102345

DO - 10.1016/j.bcmd.2019.102345

M3 - Article

AN - SCOPUS:85069726890

VL - 79

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

M1 - 102345

ER -